Shapiro–Senapathy algorithm

The Shapiro—Senapathy algorithm (S&S) algorithm is one of the most influential computational methods for identifying splice sites in eukaryotic genes. The algorithm employs a Position Weight Matrix (PWM) scoring formula to predict donor and acceptor splice sites in any given gene. This methodology has been instrumental in discovering splice sites and disease-causing splice site mutations in the human genome, and has become a standard tool in clinical genomics.

The different types of splicing mutations in genes. Mutations within the splicing regions of genes can lead to a defective transcript and protein. Depending on where exactly the mutation occurs and which "cryptic" splice site near the original site is chosen for splicing, the specific defect in the transcript and protein will vary. Frequently, splicing mutations will lead to exon skipping, intron inclusion, exon extension/truncation, and premature termination in the resulting transcript. The various defects in the transcript will in turn result in different kinds of disruption in the amino acid sequence of the protein.

The S&S algorithm has been cited in over 6,000 peer-reviewed clinical studies, and has formed the basis of widely used software, including Human Splicing Finder^[1], SROOGLE^[2],and Alamut^[3], which identify splice sites and splice site mutations that cause disease. The algorithm has uncovered splicing mutations in diseases ranging from cancers to inherited disorders, and predicted the deleterious effects of these mutations including exon skipping, intron retention, and cryptic splice site activation.

The algorithm

A splice site defines the boundary between a coding exon and a non-coding intron in eukaryotic genes. The S&S algorithm employs a sliding window, corresponding to the length of the splice site motif, to scan a gene sequence and detect potential splice sites. For each sliding window, the algorithm calculates a score by comparing the nucleotide sequence to a Position Weight Matrix (PWM) derived from known splice sites. This formula generates a percentile score, indicating the likelihood that a given sequence functions as a donor or acceptor splice site.

The majority of disease-causing mutations in the human genome are located in splice sites. Clinical genomics studies analyze the splice site scores generated by the S&S algorithm to predict the consequences of splice site mutations including exon skipping and intron retention. The algorithm’s sensitivity to single-nucleotide changes makes it a valuable tool for determining mutations that may impact RNA splicing and contribute to disease.

In addition to identifying real splice sites, the S&S algorithm has been used to discover cryptic splice sites — alternative splice sites activated by mutations — which may disrupt normal splicing. The algorithm detects mutations that lead to the activation of cryptic splice sites, which may be located proximal to real splice sites or deep within non-coding introns. It has thus played a central role in determining the causes of numerous diseases that are due to cryptic splicing.

Cancer gene discovery using S&S

Algorithm have been instrumental in identifying splice-site mutations linked to various cancers. For example, genes causing commonly occurring cancers including breast cancer,^[4][5][6] ovarian cancer,^[7][8][9] colorectal cancer,^[10][11][12] leukemia,^[13][14] head and neck cancers,^[15][16] prostate cancer,^[17][18] retinoblastoma,^[19][20] squamous cell carcinoma,^[21][22][23] gastrointestinal cancer,^[24][25] melanoma,^[26][27] liver cancer,^[28][29] Lynch syndrome,^[30][31][11] skin cancer,^[21][32][33] and neurofibromatosis^[34][35] have been found. In addition, splicing mutations in genes causing less commonly known cancers including gastric cancer,^[36][37][24] gangliogliomas,^[38][39] Li-Fraumeni syndrome, Loeys–Dietz syndrome, Osteochondromas (bone tumor), Nevoid basal cell carcinoma syndrome,^[7] and Pheochromocytomas^[9] have been identified.

Specific mutations in different splice sites in various genes causing breast cancer (e.g., BRCA1, PALB2), ovarian cancer (e.g., SLC9A3R1, COL7A1, HSD17B7), colon cancer (e.g., APC, MLH1, DPYD), colorectal cancer (e.g., COL3A1, APC, HLA-A), skin cancer (e.g., COL17A1, XPA, POLH), and Fanconi anemia (e.g., FANC, FANA) have been uncovered. The mutations in the donor and acceptor splice sites in different genes causing a variety of cancers that have been identified by S&S are shown in Table 1.

Disease type	Gene symbol	Mutation location	Original sequence	Mutated sequence	Splicing aberration
Breast cancer	BRCA1	Exon 11	AAGGTGTGT	AAAGTGTGT	Skipping of exon 12[40]
	PALB2	Exon 12	CAGGCAAGT	CAAGCAAGT	Potentially weakening the canonical donor splicing site[41]
Ovarian cancer	SLC9A3R1	Exon2	GAGGTGATG	GAGGCGATG	Significant effect in ‘splicing’[8]
Colorectal Cancer	MLH1	Exon 9	TCGGTATGT	TCAGTATGT	Skipping of exon 8 and protein truncation[10]
	MSH2	Intron 8	CAGGTATGC	CAGGCATGC	Intervening sequence, RNA processing,No amino acid change[10]
	MSH6	Intron 9	TTTTTAATTTTAAGG	TTTTTAATTTTGAGG	Intervening sequence, RNA processing,No amino acid change[10]
Skin Cancer	TGFBR1	Exon 5	TTTTGATTCTTTAGG	TTTTGATTCTTTCGG	Exon 5 skipping[21]
	ITGA6	Intron 19	TTATTTTCTAACAGG	TTATTTTCTAACACG	Skipping of the exon 20 and resulted in in-frame deletion[42]
Birt–Hogg–Dubé (BHD) syndrome	FLCN	Exon 9	GAAGTAAGC	GAAGGAAGC	Skipping of exon 9 and weak retention of 131 bp of intron 9[43]
Nevoid basal cell carcinoma	PTCH1	Intron 4	CAGGTATAT	CAGGTGTAT	Exon 4 Skipping [7]
Mesothelioma	BAP1	Exon 16	AAGGTGAGG	TAGGTGAGG	Creates a novel 5’ splice site that results in a 4 nucleotide deletion of the 3’ end of exon 16[44]

Table 1. Mutations in the donor and acceptor splice sites in different genes

Discovery of genes causing inherited disorders using S&S

Specific mutations in different splice sites in various genes that cause inherited disorders, including, for example, Type 1 diabetes (e.g., PTPN22, TCF1 (HCF-1A)), hypertension (e.g., LDL, LDLR, LPL), Marfan syndrome (e.g., FBN1, TGFBR2, FBN2), cardiac diseases (e.g., COL1A2, MYBPC3, ACTC1), eye disorders (e.g., EVC, VSX1) have been uncovered. A few example mutations in the donor and acceptor splice sites in different genes causing a variety of inherited disorders identified using S&S are shown in Table 2.

Disease type	Gene symbol	Mutation location	Original sequence	Mutated sequence	Splicing aberration
Diabetes	PTPN22	Exon 18	AAGGTAAAG	AACGTAAAG	Skipping of exon 18[45]
	TCF1	Intron 4	TTTGTGCCCCTCAGG	TTTGTGCCCCTCGGG	Skipping of exon 5[46]
Hypertension	LDL	Intron 10	TGGGTGCGT	TGGGTGCAT	Normolipidemic to classical heterozygous FH[47]
	LDLR	Intron 2	GCTGTGAGT	GCTGTGTGT	May cause splicing abnormalities through an in-silico analysis[48]
	LPL	Intron 2	ACGGTAAGG	ACGATAAGG	Cryptic splice sites is activated in vivo at the sites[49]
Marfan syndrome	FBN1	Intron 46	CAAGTAAGA	CAAGTAAAA	Exon skipping/cryptic splice site[50]
	TGFBR2	Intron 1	ATCCTGTTTTACAGA	ATCCTGTTTTACGGA	Abnormal splicing[51]
	FBN2	Intron45	TGGGTAAGT	TGGGGAAGT	Splice site alterations leading to frameshift mutations, causing a truncated protein[51]
Cardiac disease	COL1A2	Intron 46	GCTGTAAGT	GCTGCAAGT	Permitted almost exclusive use of a cryptic donor site 17 nt upstream in the exon[52]
	MYBPC3	Intron 5	CTCCATGCACACAGG	CTCCATGCACACCGG	Abnormal mRNA transcript with a premature stop codon will produce a truncated protein lacking the binding sites for myosin and titin[53]
	ACTC1	Intron 1	TTTTCTTCTCATAGG	TTTTCTTCTTATAGG	No effect [54]
Eye disorder	ABCR	Intron 30	CAGGTACCT	CAGTTACCT	Autosomal recessive RP and CRD[55]
	VSX1	Intron 5	TTTTTTTTTACAAGG	TATTTTTTTACAAGG	Aberrant splicing[56]

Table 2. Mutations in the donor and acceptor splice sites in different genes causing inherited disorders

Genes causing immune system disorders

More than 100 immune system disorders affect humans, including inflammatory bowel diseases, multiple sclerosis, systemic lupus erythematosus, bloom syndrome, familial cold autoinflammatory syndrome, and dyskeratosis congenita. The Shapiro–Senapathy algorithm has been used to discover genes and mutations involved in many immune disorder diseases, including Ataxia telangiectasia, B-cell defects, epidermolysis bullosa, and X-linked agammaglobulinemia.

Xeroderma pigmentosum, an autosomal recessive disorder is caused by faulty proteins formed due to new preferred splice donor site identified using S&S algorithm and resulted in defective nucleotide excision repair.^[27]

Type I Bartter syndrome (BS) is caused by mutations in the gene SLC12A1. S&S algorithm helped in disclosing the presence of two novel heterozygous mutations c.724 + 4A > G in intron 5 and c.2095delG in intron 16 leading to complete exon 5 skipping.^[28]

Mutations in the MYH gene, which is responsible for removing the oxidatively damaged DNA lesion are cancer-susceptible in the individuals. The IVS1+5C plays a causative role in the activation of a cryptic splice donor site and the alternative splicing in intron 1, S&S algorithm shows, guanine (G) at the position of IVS+5 is well conserved (at the frequency of 84%) among primates. This also supported the fact that the G/C SNP in the conserved splice junction of the MYH gene causes the alternative splicing of intron 1 of the β type transcript.^[29]

Splice site scores were calculated according to S&S to find EBV infection in X-linked lymphoproliferative disease.^[57] Identification of Familial tumoral calcinosis (FTC) is an autosomal recessive disorder characterized by ectopic calcifications and elevated serum phosphate levels and it is because of aberrant splicing.^[58]

Application of S&S in hospitals for clinical practice and research

The Shapiro–Senapathy (S&S) algorithm has played a significant role in advancing the diagnosis and treatment of human diseases through its application in modern clinical genomics. With the widespread adoption of next-generation sequencing (NGS) technologies, the S&S algorithm is now routinely integrated into clinical practice by geneticists and diagnostic laboratories. It is implemented in various computational tools such as Human Splicing Finder (HSF),^[1] Splice Site Finder (SSF),^[59] and Alamut Visual,^[3] which assist in interpreting the functional impact of genetic variants on RNA splicing.

The algorithm is particularly useful in identifying pathogenic splice site mutations in cases where the clinical presentation is unclear or where conventional diagnostic methods have failed to identify a causative gene. Its utility has been demonstrated across diverse patient cohorts, including individuals from different ethnic backgrounds with various cancers and inherited genetic disorders. The following are selected examples illustrating its application in clinical research.

Cancers

	Cancer type	Publication title	Year	Ethnicity	Number of patients
1	Hereditary Breast Cancer	Uncovering the clinical relevance of unclassified variants in DNA repair genes: a focus on BRCA negative Tunisian cancer families[60]	2024	Tunisian	67 Patients
2	Basel Cell Carcinoma	PTCH1 gene variants rs357564, rs2236405, rs2297086 and rs41313327, mRNA and tissue expression in basal cell carcinoma patients from Western Mexico[61]	2024	Western Mexico	250 Patients 290 Control
3	Non-Small Cell Lung Cancer	Associations between telomere attrition, genetic variants in telomere maintenance genes, and non-small cell lung cancer risk in the Jammu and Kashmir population of North India[62]	2023	India	162 Patients 561 Controls
4	Prostate Cancer	Somatic and germline aberrations in homologous recombination repair genes in Chinese prostate cancer patients[63]	2023	Chinese	721 Patients
5	Colorectal Cancer	Lynch-like syndrome is as frequent as Lynch syndrome in early-onset nonfamilial nonpolyposis colorectal cancer[64]	2023	Argentina	102 patients
6	Colorectal Cancer	Germline Variants of CYBA and TRPM4 Predispose to Familial Colorectal Cancer[65]	2022	Poland	15 Families
7	Hereditary Ovarian Cancer	The Genetic and Molecular Analyses of RAD51C and RAD51D Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population[66]	2022	French Canadians	17 Families 53 Patients
8	Thymic Carcinoma	Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature[67]	2021	Italian	15 Patients
9	Neurofibromatosis Type 1	Simultaneous Detection of NF1, SPRED1, LZTR1, and NF2 Gene Mutations by Targeted NGS in an Italian Cohort of Suspected NF1 Patients[68]	2020	Italian	250 Patients
10	Neuroendocrine Pancreatic Tumor	Identification of new candidate genes and signalling pathways associated with the development of neuroendocrine pancreatic tumours based on next generation sequencing data[69]	2020	Caucasian	24 Patients
11	Oral Cancer	Polymorphic variants of drug-metabolizing enzymes alter the risk and survival of oral cancer patients[70]	2020	Indian	909 Controls 539 Patients
12	Endometrial Cancer	Targeted sequencing of genes associated with the mismatch repair pathway in patients with endometrial cancer[71]	2020	Australia	199 patients
13	Breast cancer	The germline mutational landscape of BRCA1 and BRCA2 in Brazil[72]	2018	Brazil	649 Patients
14	Hereditary non-polyposis colorectal cancer	Prevalence and characteristics of hereditary non-polyposis colorectal cancer (HNPCC) syndrome in immigrant Asian colorectal cancer patients[10]	2017	Asian Immigrant	143 Patients
15	Renal cell cancer	Genetic screening of the FLCN gene identify six novel variants and a Danish founder mutation[73]	2016	Danish	143 individuals
16	Nevoid basal cell carcinoma syndrome	Nevoid basal cell carcinoma syndrome caused by splicing mutations in the PTCH1 gene[7]	2016	Japanese	10 Patients
17	Prostate cancer	Identification of Two Novel HOXB13 Germline Mutations in Portuguese Prostate Cancer Patients[74]	2015	Portuguese	462 Patients, 132 Controls
18	Colorectal adenomatous polyposis	Identification of Novel Causative Genes for Colorectal Adenomatous Polyposis	2015	German	181 Patients,531 Controls

Inherited disorders

	Disease name	Publication title	Year	Ethnicity	Number of patients
1	Congenital Myopathy	Exome sequencing in undiagnosed congenital myopathy reveals new genes and refines genes–phenotypes correlations[75]	2024	Multiple Population	310 Families (429 patients)
2	Neurodevelopmental Delay and Neurodevelopmental Comorbidities	Phenotypic and genetic analysis of children with unexplained neurodevelopmental delay and neurodevelopmental comorbidities in a Chinese cohort using trio-based whole-exome sequencing[76]	2024	Chinese	163 Patients
3	Congenital Cataracts	Evaluation of Genetic Testing in a Cohort of Diverse Pediatric Patients in the United States with Congenital Cataracts[77]	2023	Chicago, USA	52 Patients
4	X-linked hypophosphatemia	A genetic study of a Brazilian cohort of patients with X-linked hypophosphatemia reveals no correlation between genotype and phenotype[78]	2023	Brazil	41 Patients
5	Hereditary Cerebellar Ataxia	Molecular Characterization of Portuguese Patients with Hereditary Cerebellar Ataxia[79]	2022	Portugese	19 Families (30 Individual)
6	Stargardt disease	ABCA4 c.859-25A>G, a Frequent Palestinian Founder Mutation Affecting the Intron 7 Branchpoint, Is Associated With Early-Onset Stargardt Disease[80]	2022	Palestinian	175 patients
7	Hearing Impairment & Retinal Dystrophy	Unraveling the genetic complexities of combined retinal dystrophy and hearing impairment[81]	2021	Mexican & Iranian	59 patients
8	Angelman syndrome	New genes involved in Angelman syndrome-like: Expanding the genetic spectrum[82]	2021	Spain	14 patients
9	Acute intermittent porphyria	Molecular Analysis of 55 Spanish Patients with Acute Intermittent Porphyria[83]	2020	Spanish	55 patients
10	Hearing loss	Novel Loss-of-Function Variants in CDC14A are Associated with Recessive Sensorineural Hearing Loss in Iranian and Pakistani Patients[84]	2020	Iranian & Pakistani	2 Families
11	Non-syndromic hearing loss	GJB2 and GJB6 Genetic Variant Curation in an Argentinean Non-Syndromic Hearing-Impaired Cohort[85]	2020	Argentinean	600 patients
12	Inherited retinal diseases	Molecular genetic analysis using targeted NGS analysis of 677 individuals with retinal dystrophy[86]	2019	Denmark	677 patients
13	Odontogenesis Diseases	Genetic Evidence Supporting the Role of the Calcium Channel, CACNA1S, in Tooth Cusp and Root Patterning[87]	2018	Thai families	11 Patients,18 Controls
14	Unclear speech developmental delay	Progressive SCAR14 with unclear speech, developmental delay, tremor, and behavioral problems caused by a homozygous deletion of the SPTBN2 pleckstrin homology domain[88]	2017	Pakistani family	9 Patients, 12 controls
15	Beta-Ketothiolase Deficiency	Clinical and Mutational Characterizations of Ten Indian Patients with Beta-Ketothiolase Deficiency[89]	2016	Indian	10 Patients
16	Bardet-Biedl Syndrome	The First Nationwide Survey and Genetic Analyses of Bardet-Biedl Syndrome in Japan[90]	2015	Japan	38 Patients(Disease identified in 9 Patients)
17	Dent's disease	Dent's disease in children: diagnostic and therapeutic consideration[91]	2015	Poland	10 Patients
18	Atypical Haemolytic Uraemic Syndrome	Genetics Atypical hemolytic-uremic syndrome[92]	2015	Newcastle cohort	28 Families, 7 Sporadic patients
19	Age-related Macular Degeneration and Stargardt disease	Genetics of Age-related Macular Degeneration and Stargardt disease in South African populations[93]	2015	African Populations	32 Patients

S&S - Algorithm for identifying splice sites, exons and split genes

The Shapiro–Senapathy algorithm (SSA) was developed to identify splice sites in uncharacterized genomic sequences, with early applications in the Human Genome Project.^[94][95] The method introduced a Position Weight Matrix (PWM)-based approach to analyze splicing sequences across eukaryotic organisms, marking the first computational framework to systematically define splice sites using probabilistic scoring.

Key innovations of the algorithm included:

1. Exon Detection – Exons were defined as sequences bounded by acceptor and donor splice sites with S&S scores above a threshold, requiring an open reading frame (ORF) for validation.
2. Gene Prediction – The method enabled the identification of complete genes by assembling predicted exons, forming a basis for later gene-finding tools.
3. Mutation Analysis – The algorithm distinguishes deleterious splice-site mutations (which disrupt protein function by lowering S&S scores) from neutral variations. This capability allowed researchers to study disease-linked cryptic splice sites in humans, animals, and plants.

SSA's PWM-based framework influenced subsequent computational methods, including machine learning and neural network approaches, for splice-site prediction and alternative splicing research. It remains a foundational tool in genomics and disease studies.

Discovering the mechanisms of aberrant splicing in diseases

The Shapiro–Senapathy algorithm has been used to determine the various aberrant splicing mechanisms in genes due to deleterious mutations in the splice sites, which cause numerous diseases. Deleterious splice site mutations impair the normal splicing of the gene transcripts, and thereby make the encoded protein defective. A mutant splice site can become “weak” compared to the original site, due to which the mutated splice junction becomes unrecognizable by the spliceosomal machinery. This can lead to the skipping of the exon in the splicing reaction, resulting in the loss of that exon in the spliced mRNA (exon-skipping). On the other hand, a partial or complete intron could be included in the mRNA due to a splice site mutation that makes it unrecognizable (intron inclusion). A partial exon-skipping or intron inclusion can lead to premature termination of the protein from the mRNA, which will become defective leading to diseases. The S&S has thus paved the way to determine the mechanisms by which a deleterious mutation could lead to a defective protein, resulting in different diseases depending on which gene is affected.

Examples of splicing aberrations

Disease type	Gene symbol	Mutation location	Original donor/acceptor	Mutated donor/acceptor	Aberration effect
Colon Cancer	APC	Intron 2	AAGGTAGAT	AAGGAAGAT	Skipping of Exon 3[96]
Colorectal cancer	MSH2	Exon 15	GAGGTTTGT	GAGGTTTCT	Skipping of Exon 15[97]
Retinoblastoma	RB1	Intron 23	TCTTAACTTGACAGA	TCTTAACGTGACAGA	New splice acceptor, intron inclusion[19]
Trophic benign epidermolysis bullosa	COL17A1	Intron 51	AGCGTAAGT	AGCATAAGT	lead to exon skipping, intron inclusion, or the use of a cryptic splice site, resulting in either a truncated protein or a protein lacking a small region of the coding sequence[98]
Choroideremia	CHM	Intron 3	CAGGTAAAG	CAGATAAAG	Premature termination codon[99]
Cowden syndrome	PTEN	Intron 4	GAGGTAGGT	GAGATAGGT	Premature termination codon within exon 5[49]

An example of splicing aberration (exon skipping) caused by a mutation in the donor splice site in the exon 8 of MLH1 gene that led to colorectal cancer is given below. This example shows that a mutation in a splice site within a gene can lead to a profound effect in the sequence and structure of the mRNA, and the sequence, structure and function of the encoded protein, leading to disease.

Exon Skipping caused by a donor mutation in the gene MLH1 leading to colorectal cancer. The generation of a mRNA from a split gene involves the transcription of the gene into the primary RNA transcript, and the precise removal of the introns and the joining of the exons from the primary RNA transcript. A deleterious mutation within the splicing signals (donor or acceptor splice sites) can affect the recognition of the correct splice junction and lead to an aberration in the joining of the authentic exons. Depending on if the mutation occurs within the donor or the acceptor site, and the particular base that is mutated within the splice sequence, the aberration could lead to the skipping of a complete or partial exon, or the inclusion of a partial intron or a cryptic exon in the mRNA produced by the splicing process. Either of these situations will usually lead to a premature stop codon in the mRNA and result in a completely defective protein. The S&S algorithm aids in determining which splice site and exon in a gene are mutated, and the S&S score of the mutated splice site aids in determining the type of splicing aberration and the resulting mRNA structure and sequence. The example gene MLH1 affected in colorectal cancer is shown in the figure. It was found using the S&S algorithm that a mutation in the donor splice site in exon 8 led to the skipping of the exon 8. The mRNA thus lacks the sequence corresponding to exon 8 (sequence positions are shown in the figure). This causes a frame shift in the mRNA coding sequence at amino acid position 226, leading to premature protein truncation at amino acid position 233. This mutated protein is completely defective, which has led to colorectal cancer in the patient.

S&S in cryptic splice sites research and medical applications

The proper identification of splice sites has to be highly precise as the consensus splice sequences are very short and there are many other sequences similar to the authentic splice sites within gene sequences, which are known as cryptic, non-canonical, or pseudo splice sites. When an authentic or real splice site is mutated, any cryptic splice sites present close to the original real splice site could be erroneously used as authentic site, resulting in an aberrant mRNA. The erroneous mRNA may include a partial sequence from the neighboring intron or lose a partial exon, which may result in a premature stop codon. The result may be a truncated protein that would have lost its function completely.

Shapiro–Senapathy algorithm can identify the cryptic splice sites, in addition to the authentic splice sites. Cryptic sites can often be stronger than the authentic sites, with a higher S&S score. However, due to the lack of an accompanying complementary donor or acceptor site, this cryptic site will not be active or used in a splicing reaction. When a neighboring real site is mutated to become weaker than the cryptic site, then the cryptic site may be used instead of the real site, resulting in a cryptic exon and an aberrant transcript.

Numerous diseases have been caused by cryptic splice site mutations or usage of cryptic splice sites due to the mutations in authentic splice sites.^{[100][101][102][103][104]}

S&S in animal and plant genomics research

S&S has also been used in RNA splicing research in many animals^{[105][106][107][108][109]} and plants.^{[110][111][112][113][114]}

The mRNA splicing plays a fundamental role in gene functional regulation. Very recently, it has been shown that A to G conversions at splice sites can lead to mRNA mis-splicing in Arabidopsis.^[110] The splicing and exon–intron junction prediction coincided with the GT/AG rule (S&S) in the Molecular characterization and evolution of carnivorous sundew (Drosera rotundifolia L.) class V b-1,3-glucanase.^[111] Unspliced (LSDH) and spliced (SSDH) transcripts of NAD+ dependent sorbitol dehydroge nase (NADSDH) of strawberry (Fragaria ananassa Duch., cv. Nyoho) were investigated for phytohormonal treatments.^[112]

Ambra1 is a positive regulator of autophagy, a lysosome-mediated degradative process involved both in physiological and pathological conditions. Nowadays, this function of Ambra1 has been characterized only in mammals and zebrafish.^[106] Diminution of rbm24a or rbm24b gene products by morpholino knockdown resulted in significant disruption of somite formation in mouse and zebrafish.^[107] Dr.Senapathy algorithm used extensively to study intron-exon organization of fut8 genes. The intron-exon boundaries of Sf9 fut8 were in agreement with the consensus sequence for the splicing donor and acceptor sites concluded using S&S.^[108]